Suzanne Schindler, MD, PhD, Washington University in St. Louis School of Medicine, St. Louis, MO, discusses recent developments in fluid biomarker research for the diagnosis of Alzheimer’s disease (AD). Multiple fluid biomarkers, like p-tau217 and MTBR-tau243, have demonstrated diagnostic accuracy in identifying cognitively impaired individuals with amyloid or tau pathology. Some blood-based biomarkers are expected to receive FDA approval in 2025 and become available for clinical care. Fluid biomarkers are also being applied in patient selection for clinical trials and to examine non-AD causes of dementia. This interview took place at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
